1
|
Li D, Hua Y, Jiang L, Huang Y, Yue J, Wu Y, Chen Y. Cyclic Guanosine Monophosphate (cGMP)-Dependent Protein Kinase II Blocks Epidermal Growth Factor (EGF)/Epidermal Growth Factor Receptor (EGFR)-Induced Biological Effects on Osteosarcoma Cells. Med Sci Monit 2018; 24:1997-2002. [PMID: 29617357 PMCID: PMC5900801 DOI: 10.12659/msm.905892] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
Background The present work was performed to detect the potential inhibitory effect of cyclic guanosine monophosphate (cGMP)-dependent protein kinase II (PKG II) on epidermal growth factor (EGF) receptor-induced biological activity and related signal cascades in osteosarcoma cells. Material/Methods We transfected the osteosarcoma MG-63 cell line with an adenoviral vector encoding PKG II cDNA (Ad-PKGII) and incubated the transfected cells with 250 μM 8-pCPT-cGMP to activate the PKG II. We stimulated the MG-63 cells with100 ng/ml EGF, and then detected their proliferation using a CCK-8 assay. Transwell assay was used to examine MG-63 cell migration; and Western blot analysis was used to detect expression of matrix metalloproteinase 9 (MMP-9) and activation of ERK and Akt. Results Stimulating cells by 100 ng/ml EGF promoted MG-63 cell proliferation and migration, ERK and Akt phosphorylation, and MMP-9 expression. These effects of EGF were inhibited in MG-63 cells infected with Ad-PKGII and incubated with 8-pCPT-cGMP. Conclusions Our results demonstrate that Ad-PKGII infection significantly inhibited EGF-induced proliferation and migration, as well as the associated-signal cascades; which indicates that PKG II might be a potential anti-cancer factor.
Collapse
Affiliation(s)
- Dapeng Li
- Department of Orthopaedics, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, China (mainland)
| | - Ye Hua
- Department of Orthopaedics, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, China (mainland)
| | - Lu Jiang
- Department of Physiology, Medical College of Jiangsu Universit, Zhenjiang, Jiangsu, China (mainland)
| | - Yonghui Huang
- Department of Orthopaedics, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, China (mainland)
| | - Jiawei Yue
- Department of Orthopaedics, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, China (mainland)
| | - Yan Wu
- Department of Physiology, Medical College of Jiangsu University, Zhenjiang, Jiangsu, China (mainland)
| | - Yongchang Chen
- Department of Physiology, Medical College of Jiangsu University, Zhenjiang, Jiangsu, China (mainland)
| |
Collapse
|
2
|
Wu Y, Liu Y, Cai Z, Qin H, Li H, Su W, Wang Y, Qian H, Jiang L, Wu M, Pang J, Chen Y. Protein Kinases Type II (PKG II) Combined with L-Arginine Significantly Ameliorated Xenograft Tumor Development: Is L-Arginine a Potential Alternative in PKG II Activation? Med Sci Monit 2018; 24:736-742. [PMID: 29401205 PMCID: PMC5810367 DOI: 10.12659/msm.906213] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
BACKGROUND The mammalian cyclic guanosine monophosphate (cGMP)-dependent protein kinases type II (PKG II) plays critical physiological or pathological functions in different tissues. However, the biological effects of PKG II are dependent on cGMP. Published data indicated that L-arginine (L-Arg) promoted NO production, NO can activate soluble guanylate cyclase (sGC), and catalyzes guanosine triphosphate (GTP) into cGMP, which suggested L-Arg could activate PKG II. Therefore, the present work was performed to address: (i) whether L-Arg could be a potential alternative in PKG II activation, and (ii) whether L-Arg also contributes to PKG II against cancer. MATERIAL AND METHODS Nude BALB/c mice were inoculated with human MCF-7, HepG2, and SW480 cell lines via subcutaneous (s.c.) injecting. After 7 days of inoculation, Ad-PKG II was injected into the cancer tissues every 4 days, and the next day 10 μmol/mouse L-Arg was administered. Western blotting and immunohistochemistry were used to assess protein expression. RESULTS Our results demonstrated that L-Arg significantly activated PKG II and effectively ameliorated xenograft tumor development through inhibiting cancer growth, angiogenesis, and metastasis, which was partially dependent on blocking of epidermal growth factor receptor (EGFR) activity, as well as downstream signaling pathways such as Erk1/2. CONCLUSIONS Our results provide an exciting new insight: L-Arg is a potential alternative to PKG II activation.
Collapse
Affiliation(s)
- Yan Wu
- Department of Physiology, School of Medicine, Jiangsu University, Zhenjiang, Jiangsu, China (mainland).,The Central Laboratory, The Fourth Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, China (mainland)
| | - Ying Liu
- Department of Physiology, School of Medicine, Jiangsu University, Zhenjiang, Jiangsu, China (mainland)
| | - Zhensheng Cai
- Department of Physiology, School of Medicine, Jiangsu University, Zhenjiang, Jiangsu, China (mainland)
| | - Huijuan Qin
- Department of Physiology, School of Medicine, Jiangsu University, Zhenjiang, Jiangsu, China (mainland)
| | - Hongfan Li
- Department of Physiology, School of Medicine, Jiangsu University, Zhenjiang, Jiangsu, China (mainland)
| | - Wenbin Su
- Department of Physiology, School of Medicine, Jiangsu University, Zhenjiang, Jiangsu, China (mainland)
| | - Ying Wang
- Department of Physiology, School of Medicine, Jiangsu University, Zhenjiang, Jiangsu, China (mainland)
| | - Hai Qian
- Department of Physiology, School of Medicine, Jiangsu University, Zhenjiang, Jiangsu, China (mainland)
| | - Lu Jiang
- Department of Physiology, School of Medicine, Jiangsu University, Zhenjiang, Jiangsu, China (mainland)
| | - Min Wu
- Department of Physiology, School of Medicine, Jiangsu University, Zhenjiang, Jiangsu, China (mainland)
| | - Ji Pang
- Department of Physiology, School of Medicine, Jiangsu University, Zhenjiang, Jiangsu, China (mainland)
| | - Yongchang Chen
- Department of Physiology, School of Medicine, Jiangsu University, Zhenjiang, Jiangsu, China (mainland)
| |
Collapse
|
3
|
Wu Y, Yuan M, Su W, Zhu M, Yao X, Wang Y, Qian H, Jiang L, Tao Y, Wu M, Pang J, Chen Y. The constitutively active PKG II mutant effectively inhibits gastric cancer development via a blockade of EGF/EGFR-associated signalling cascades. Ther Adv Med Oncol 2018; 10:1758834017751635. [PMID: 29434677 PMCID: PMC5802699 DOI: 10.1177/1758834017751635] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2017] [Accepted: 11/06/2017] [Indexed: 12/30/2022] Open
Abstract
Type II cyclic guanosine monophosphate (cGMP)-dependent protein kinase (PKG II) is a membrane-anchored enzyme expressed mainly in the intestinal mucosa and the brain, and is associated with various physiological or pathological processes. Upregulation of PKG II is known to induce apoptosis and inhibit proliferation and metastasis of cancer cells. The inhibitory effect of PKG II has been shown to be dependent on the inhibition of the activation of epidermal growth factor receptor (EGFR) and blockade of EGFR downstream signal transduction in vitro. However, it remains unclear whether similar phenomena/mechanisms exist in vivo and whether these effects are independent of cGMP or cGMP analogues. In the present work, nude mice with transplanted orthotopic tumours were infected with adenovirus encoding cDNA of constitutively active PKG II mutant (Ad-a-PKG II) and the effect of constitutively active PKG II (a-PKG II) on tumour development was detected. The results showed that a-PKG II effectively ameliorated gastric tumour development through delaying the growth, inducing the apoptosis, and inhibiting the metastasis and angiogenesis. The effect was related to blockade of EGFR activation and abrogation of the downstream signalling cascades. These findings provide novel insight which will benefit the development of new cancer therapies.
Collapse
Affiliation(s)
- Yan Wu
- Department of Physiology, School of Medicine, Jiangsu University. 301 Xuefu Road; and The Central Laboratory, the Fourth Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, 212013, China
| | - Miaomiao Yuan
- Department of Physiology, Jiangsu University, Zhenjiang, China
| | - Wenbin Su
- Department of Physiology, Jiangsu University, Zhenjiang, China
| | - Miaolin Zhu
- Department of Pathology, Jiangsu Cancer Hospital, Nanjing, China
| | - Xiaoyuan Yao
- Department of Basic Medicine, Changchun Medical College, Changchun, China
| | - Ying Wang
- Department of Physiology, Jiangsu University, Zhenjiang, China
| | - Hai Qian
- Department of Physiology, Jiangsu University, Zhenjiang, China
| | - Lu Jiang
- Department of Physiology, Jiangsu University, Zhenjiang, China
| | - Yan Tao
- Department of Physiology, Jiangsu University, Zhenjiang, China
| | - Min Wu
- Department of Physiology, Jiangsu University, Zhenjiang, China
| | - Ji Pang
- Department of Physiology, Jiangsu University, Zhenjiang, China
| | - Yongchang Chen
- Department of Physiology, School of Medicine, Jiangsu University. 301 Xuefu Road; Zhenjiang, Jiangsu, 212013, China
| |
Collapse
|